EUVIMEDEUVIMED entdecken
Open Access

Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer

Ruben Raychaudhuri iD, Isla P Garraway, Kara N Maxwell, Matt Rettig, Heena Desai, Martin W Schoen iD, Michael T Schweizer, Himisha Beltran iD, Peter S Nelson iD, Bruce Montgomery iD

JCO Precision Oncology · 2025

DOI: 10.1200/po-25-00341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Ruben Raychaudhuri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Washington, VA Puget Sound HCS, Seattle, WA. Hauptthemen laut MEDLINE: Retinoblastoma Binding Proteins, Prostatic Neoplasms, Castration-Resistant, Ubiquitin-Protein Ligases, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Emerging evidence suggests that RB1 inactivation may be a strong predictor of poor survival for men with prostate cancer (PC); however, large-scale validation is lacking. METHODS We analyzed whether RB1 alterations are associated with inferior survival in advanced PC and evaluated the impact of co-occurring genomic alterations on outcomes using retrospective data from the Veteran's Health Administration and Veterans Affairs Multi-Omics Analysis Platform for Prostate Cancer from 2016 to 2023. RESULTS The primary outcome was overall survival (OS) from onset of metastatic castration-resistant prostate cancer (mCRPC), as well as OS from initiation of life-prolonging therapy other than androgen deprivation therapy, and time to development of mCRPC. Eighty-seven (3.5%) of the 2,512 included patients had an RB1 alteration detected. The median age at diagnosis in the RB1 -altered group was 71 (IQR, 65-76) years, and 68 (IQR, 62-73) years in the RB1 wild-type group. The median overall survival from diagnosis of mCRPC was 1.31 years (95% CI, 0.89 to 1.84) in those with an RB1 alteration compared with 2.99 years (95% CI, 2.79 to 3.23). RB1 alteration alone conferred similar poor prognosis when compared with patients who had combined PTEN and TP53 alterations. A dose effect was seen with increasing numbers of tumor suppressor genes (TSGs— RB1 , TP53 , and PTEN ) conferring poorer outcomes. The median survival of patients from diagnosis of mCRPC with zero, one, two, and three TSGs was 3.74, 2.61, 1.61, and 0.87 years, respectively. BRCA2 alterations were not associated with significantly worse outcomes unless accompanied by RB1 alteration. CONCLUSION In this large, real-world cohort of men with mCRPC, RB1 alterations emerged as a strong indicator of poor prognosis and can be used to stratify studies alone or in conjunction with other TSG alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinoblastoma Binding ProteinsProstatic Neoplasms, Castration-ResistantUbiquitin-Protein LigasesProstatic NeoplasmsHumansMaleAgedPrognosisRetrospective StudiesMiddle AgedNeoplasm Metastasis

Substanzen

RB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Division of Hematology and Oncology, University of Washington, VA Puget Sound HCS, Seattle, WA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • David Geffen School of Medicine, University of California, Los Angeles, CA.
  • VA Greater Los Angeles Healthcare System, Los Angeles, CA.
  • Department of Medicine, Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Saint Louis Veterans Affairs Medical Center, Saint Louis, MO.

ORCID-Profile: Ruben Raychaudhuri, Martin W Schoen, Himisha Beltran, Peter S Nelson, Bruce Montgomery

Förderung

  • NCI NIH HHS

Zitieren

APA

Raychaudhuri, R., Garraway, I. P., Maxwell, K. N., Rettig, M., Desai, H., Schoen, M. W., Schweizer, M. T., Beltran, H., Nelson, P. S., & Montgomery, B. (2025). Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-25-00341

Vancouver

Raychaudhuri R, Garraway IP, Maxwell KN, Rettig M, Desai H, Schoen MW, et al. Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-25-00341

BibTeX
@article{Raychaudhuri2025,
  author = {Raychaudhuri, Ruben and Garraway, Isla P and Maxwell, Kara N and Rettig, Matt and Desai, Heena and Schoen, Martin W and Schweizer, Michael T and Beltran, Himisha and Nelson, Peter S and Montgomery, Bruce},
  title = {Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-25-00341}
}
Kostenlos starten →